Antihistamines News and Research

RSS

Simple measures to handle fall allergies in children

Perhaps you think of allergies as being most bothersome- and most likely to occur- during the spring and summer months, when pollens and molds are seemingly everywhere.

8 Oct 2019

Study finds rise in off-label medication orders for children

U.S. physicians are increasingly ordering medications for children for conditions that are not approved by the Food and Drug Administration, according to a Rutgers study.

16 Sep 2019

Researchers discover potential of antihistamines that cause death of leukemic stem cells

Ruth M. Risueño leads the Leukaemic Stem Cell group of the Josep Carreras Leukaemia Research Institute. This group investigates Acute Myeloid Leukemia and the cell population responsible for the disease spreading, persisting, and if it has been treated and overcome, reappear.

6 Sep 2019

Genetics may play a role in allergic reactions to contrast media

Researchers in South Korea have found that patients with family and personal history of allergic reactions to contrast media are at risk for future reactions, according to a large study published in the journal Radiology.

4 Sep 2019

Physicians more likely to recommend antihistamines for respiratory infections in children

For respiratory infections in children under 12, physicians are increasingly more likely to recommend antihistamines and less likely to recommend cough and cold medicines, a Rutgers study found.

29 Jul 2019

Children with medical emergencies get only limited help during airline flights

Children afflicted with medical emergencies during commercial airline trips tend to have common ailments such as vomiting, fever or allergic reactions - events that should be easily treated, according to a study led by Duke Health researchers.

25 Jul 2019

Common medications can masquerade as dementia in seniors

By all accounts the woman, in her late 60s, appeared to have severe dementia. She was largely incoherent. Her short-term memory was terrible. She couldn't focus on questions that medical professionals asked her.

18 Jul 2019

Treatment guidelines for managing anaphylaxis in children need to be reassessed

Treatment guidelines for managing anaphylaxis in children should be reassessed, according to a new Canadian study published in the Journal of Allergy and Clinical Immunology: In Practice.

31 May 2019

Study uncovers Achilles' heel of lethal brain tumor

Glioblastoma is the most prevalent and also the most lethal type of brain tumor in adults, with no curative treatment currently available.

10 May 2019

Study confirms QT-prolonging effects of grapefruit juice

Grapefruit juice is already listed as a substance to avoid when taking QT-prolonging medications because it increases the toxicity of many drugs.

9 May 2019

Regular dietary peanut consumption after immunotherapy may extend allergy treatment benefits

Regular dietary peanut consumption after completing oral immunotherapy or sublingual immunotherapy for peanut allergy may provide continued protection against accidental exposures to the allergen, according to a new study led by Edwin Kim, MD, who presented the findings at the annual American Academy of Allergy, Asthma and Immunology conference in San Francisco.

25 Feb 2019

New ingestible capsule can be controlled using Bluetooth wireless technology

Researchers at MIT, Draper, and Brigham and Women's Hospital have designed an ingestible capsule that can be controlled using Bluetooth wireless technology. The capsule, which can be customized to deliver drugs, sense environmental conditions, or both, can reside in the stomach for at least a month, transmitting information and responding to instructions from a user's smartphone.

13 Dec 2018

Study identifies new potential target for treating major common diseases

There is a large, untapped potential for developing drugs against cancer, fibrosis and cardiovascular diseases by targeting a family of receptors known as Frizzleds, researchers at Karolinska Institutet in Sweden believe. In a new study published in Science Signaling, they identify how these receptors are activated in the cell membrane and the processes that are then triggered within the cell.

4 Dec 2018

Researchers identify pathway to resolve allergic asthma

A group of Brazilian researchers succeeded in preventing allergic asthma from progressing in experimental models by increasing the amount of a protein. This increase, in turn, blocked the CD4+ T lymphocytes responsible for producing a cytokine that triggers a cascade of events resulting in the onset and progression of the disease.

6 Nov 2018

Meta-analysis reveals effective treatment options for urticarial vasculitis

What treatments are available for patients with the rare inflammatory disease known as urticarial vasculitis? How effective are these treatments? Researchers from Charité - Universitätsmedizin Berlin embarked on a systematic review and meta-analysis to address these questions.

30 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

FDA approves new treatment for people with hairy cell leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the European Commission (EC) has granted marketing authorization for ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy.

30 Aug 2018